| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 22 | 2023 | 54 | 7.660 |
Why?
|
| Heart Transplantation | 16 | 2023 | 48 | 5.790 |
Why?
|
| Heart Failure | 22 | 2023 | 695 | 4.530 |
Why?
|
| Mitral Valve Insufficiency | 6 | 2021 | 32 | 3.600 |
Why?
|
| Lung Transplantation | 8 | 2024 | 14 | 3.360 |
Why?
|
| Mitral Valve | 6 | 2021 | 39 | 2.230 |
Why?
|
| Tissue Donors | 8 | 2021 | 207 | 1.950 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2021 | 50 | 1.850 |
Why?
|
| Tissue and Organ Procurement | 5 | 2020 | 99 | 1.620 |
Why?
|
| Humans | 64 | 2024 | 32840 | 1.470 |
Why?
|
| Registries | 6 | 2020 | 320 | 1.430 |
Why?
|
| Graft Rejection | 2 | 2024 | 241 | 1.390 |
Why?
|
| Coronary Artery Disease | 5 | 2022 | 413 | 1.370 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2022 | 22 | 1.350 |
Why?
|
| Thrombosis | 3 | 2020 | 81 | 1.330 |
Why?
|
| Donor Selection | 3 | 2020 | 36 | 1.320 |
Why?
|
| Diabetes Complications | 2 | 2023 | 183 | 1.280 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2019 | 81 | 1.230 |
Why?
|
| Coronary Sinus | 2 | 2018 | 2 | 1.160 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2019 | 9 | 1.140 |
Why?
|
| Treatment Outcome | 19 | 2023 | 3441 | 1.110 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2019 | 168 | 1.100 |
Why?
|
| Middle Aged | 25 | 2022 | 12146 | 1.020 |
Why?
|
| Retrospective Studies | 18 | 2023 | 3708 | 1.000 |
Why?
|
| Male | 31 | 2022 | 19675 | 1.000 |
Why?
|
| Coronary Artery Bypass | 4 | 2019 | 111 | 0.950 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2022 | 30 | 0.930 |
Why?
|
| Myocardium | 3 | 2021 | 191 | 0.910 |
Why?
|
| Propensity Score | 3 | 2021 | 48 | 0.890 |
Why?
|
| Ubiquitin | 3 | 2023 | 18 | 0.880 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 1464 | 0.880 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2023 | 22 | 0.870 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2024 | 2 | 0.870 |
Why?
|
| Reoperation | 4 | 2021 | 260 | 0.860 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2022 | 6 | 0.810 |
Why?
|
| Blood Coagulation Factors | 2 | 2020 | 5 | 0.790 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2023 | 57 | 0.790 |
Why?
|
| Waiting Lists | 2 | 2020 | 36 | 0.780 |
Why?
|
| Ventricular Function, Right | 2 | 2019 | 19 | 0.770 |
Why?
|
| Pneumonectomy | 2 | 2019 | 14 | 0.760 |
Why?
|
| Transposition of Great Vessels | 1 | 2022 | 4 | 0.740 |
Why?
|
| Heart Ventricles | 3 | 2019 | 146 | 0.730 |
Why?
|
| Graft Survival | 2 | 2020 | 313 | 0.700 |
Why?
|
| Heart Valve Prosthesis | 2 | 2021 | 60 | 0.680 |
Why?
|
| Symbiosis | 1 | 2021 | 4 | 0.680 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 252 | 0.670 |
Why?
|
| Female | 23 | 2023 | 20293 | 0.660 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 18 | 0.650 |
Why?
|
| Transplantation Immunology | 1 | 2020 | 29 | 0.640 |
Why?
|
| Patient Selection | 3 | 2020 | 281 | 0.630 |
Why?
|
| Exosomes | 1 | 2020 | 45 | 0.630 |
Why?
|
| HLA Antigens | 1 | 2020 | 41 | 0.630 |
Why?
|
| Warfarin | 1 | 2020 | 34 | 0.630 |
Why?
|
| Liver Failure | 1 | 2019 | 21 | 0.620 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2019 | 6 | 0.620 |
Why?
|
| Burkholderia Infections | 1 | 2019 | 1 | 0.620 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2019 | 26 | 0.610 |
Why?
|
| Perioperative Care | 1 | 2020 | 56 | 0.610 |
Why?
|
| Transplants | 1 | 2019 | 23 | 0.610 |
Why?
|
| Robotics | 1 | 2021 | 127 | 0.610 |
Why?
|
| Haptoglobins | 1 | 2019 | 5 | 0.610 |
Why?
|
| Lung Diseases | 1 | 2019 | 48 | 0.600 |
Why?
|
| Arteriovenous Malformations | 1 | 2018 | 9 | 0.580 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 19 | 0.580 |
Why?
|
| Aortic Valve | 2 | 2021 | 60 | 0.580 |
Why?
|
| Liver Transplantation | 1 | 2019 | 183 | 0.580 |
Why?
|
| Cardiotonic Agents | 3 | 2015 | 43 | 0.580 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 8 | 0.580 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 5 | 0.580 |
Why?
|
| Indans | 3 | 2015 | 34 | 0.580 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 27 | 0.570 |
Why?
|
| Signal Transduction | 3 | 2017 | 688 | 0.570 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 39 | 0.570 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 21 | 0.570 |
Why?
|
| Adult | 13 | 2022 | 9576 | 0.570 |
Why?
|
| Myocytes, Cardiac | 5 | 2020 | 94 | 0.550 |
Why?
|
| Aged | 15 | 2022 | 10557 | 0.550 |
Why?
|
| Thoracotomy | 1 | 2018 | 25 | 0.550 |
Why?
|
| Equipment Failure | 1 | 2018 | 28 | 0.550 |
Why?
|
| Mitral Valve Stenosis | 1 | 2017 | 10 | 0.540 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 29 | 0.540 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 30 | 0.540 |
Why?
|
| Catheterization | 1 | 2018 | 57 | 0.540 |
Why?
|
| Genotype | 1 | 2019 | 731 | 0.530 |
Why?
|
| Risk Factors | 9 | 2022 | 3981 | 0.530 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 51 | 0.530 |
Why?
|
| Cardiology | 2 | 2021 | 108 | 0.470 |
Why?
|
| Imidazoline Receptors | 1 | 2012 | 3 | 0.390 |
Why?
|
| Acute Disease | 2 | 2024 | 259 | 0.340 |
Why?
|
| Myocardial Revascularization | 1 | 2011 | 41 | 0.340 |
Why?
|
| Ventricular Remodeling | 3 | 2017 | 64 | 0.320 |
Why?
|
| General Surgery | 1 | 2011 | 86 | 0.320 |
Why?
|
| Echocardiography | 3 | 2019 | 183 | 0.310 |
Why?
|
| Animals | 9 | 2024 | 7594 | 0.310 |
Why?
|
| Survival Rate | 4 | 2019 | 895 | 0.310 |
Why?
|
| Blood Coagulation | 2 | 2020 | 18 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 412 | 0.300 |
Why?
|
| Time Factors | 6 | 2021 | 2190 | 0.300 |
Why?
|
| Coronary Angiography | 2 | 2022 | 162 | 0.290 |
Why?
|
| Prosthesis Design | 2 | 2019 | 102 | 0.290 |
Why?
|
| Referral and Consultation | 2 | 2019 | 147 | 0.250 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2005 | 7 | 0.240 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 2285 | 0.240 |
Why?
|
| Cardiomegaly | 1 | 2005 | 31 | 0.230 |
Why?
|
| RNA, Messenger | 3 | 2023 | 499 | 0.230 |
Why?
|
| Neuroimmunomodulation | 1 | 2024 | 1 | 0.220 |
Why?
|
| Vagus Nerve | 1 | 2024 | 30 | 0.210 |
Why?
|
| Israel | 4 | 2023 | 7 | 0.210 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 129 | 0.200 |
Why?
|
| Cytokines | 1 | 2024 | 247 | 0.200 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 11 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2019 | 1465 | 0.190 |
Why?
|
| Pregnancy Complications | 1 | 2023 | 111 | 0.190 |
Why?
|
| Lung | 2 | 2023 | 266 | 0.180 |
Why?
|
| Myocardial Infarction | 2 | 2017 | 486 | 0.180 |
Why?
|
| Mice | 3 | 2023 | 2527 | 0.170 |
Why?
|
| Receptors, Virus | 1 | 2021 | 15 | 0.170 |
Why?
|
| Endocarditis | 1 | 2021 | 18 | 0.170 |
Why?
|
| Inflammation | 1 | 2024 | 536 | 0.170 |
Why?
|
| Bioprosthesis | 1 | 2021 | 61 | 0.160 |
Why?
|
| Fibroblasts | 1 | 2020 | 115 | 0.160 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2019 | 17 | 0.160 |
Why?
|
| Recovery of Function | 2 | 2018 | 203 | 0.160 |
Why?
|
| Sternotomy | 1 | 2019 | 4 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 178 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 24 | 0.150 |
Why?
|
| Heart | 1 | 2020 | 185 | 0.150 |
Why?
|
| Hemostasis | 1 | 2019 | 7 | 0.150 |
Why?
|
| Brain Death | 1 | 2019 | 27 | 0.150 |
Why?
|
| Ischemia | 1 | 2019 | 104 | 0.150 |
Why?
|
| Regional Health Planning | 1 | 2019 | 9 | 0.150 |
Why?
|
| Benchmarking | 1 | 2019 | 25 | 0.150 |
Why?
|
| Algorithms | 2 | 2019 | 513 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2019 | 220 | 0.150 |
Why?
|
| Thromboembolism | 1 | 2019 | 38 | 0.150 |
Why?
|
| Recurrence | 1 | 2019 | 282 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 17 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2020 | 136 | 0.140 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 84 | 0.140 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 6 | 0.140 |
Why?
|
| Frail Elderly | 1 | 2019 | 71 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 34 | 0.140 |
Why?
|
| Rats | 4 | 2012 | 1609 | 0.140 |
Why?
|
| Alleles | 1 | 2019 | 253 | 0.140 |
Why?
|
| California | 1 | 2018 | 66 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 679 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 82 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 326 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2019 | 44 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2019 | 107 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2020 | 469 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2020 | 189 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 59 | 0.140 |
Why?
|
| Axillary Artery | 1 | 2018 | 2 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 113 | 0.140 |
Why?
|
| Platelet Function Tests | 1 | 2017 | 7 | 0.140 |
Why?
|
| Platelet Activation | 1 | 2017 | 14 | 0.140 |
Why?
|
| Adenosine | 1 | 2017 | 59 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 410 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 85 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2018 | 123 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2017 | 60 | 0.130 |
Why?
|
| Walking | 1 | 2018 | 210 | 0.130 |
Why?
|
| Hospitalization | 1 | 2019 | 490 | 0.120 |
Why?
|
| Health Personnel | 3 | 2021 | 130 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2022 | 2330 | 0.120 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2015 | 18 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 429 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 204 | 0.110 |
Why?
|
| Incidence | 1 | 2018 | 1239 | 0.110 |
Why?
|
| Myocarditis | 1 | 2014 | 9 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2012 | 290 | 0.100 |
Why?
|
| Obesity | 1 | 2021 | 1152 | 0.100 |
Why?
|
| Device Removal | 1 | 2014 | 41 | 0.100 |
Why?
|
| PC12 Cells | 1 | 2012 | 7 | 0.100 |
Why?
|
| Benzofurans | 1 | 2012 | 5 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 23 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 36 | 0.100 |
Why?
|
| Binding Sites | 1 | 2012 | 129 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2018 | 828 | 0.090 |
Why?
|
| Imidazoles | 1 | 2012 | 92 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 13 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2023 | 308 | 0.090 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 65 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 27 | 0.090 |
Why?
|
| Apoptosis | 2 | 2019 | 363 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 622 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2011 | 754 | 0.080 |
Why?
|
| Hypertrophy | 2 | 2011 | 29 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 14 | 0.080 |
Why?
|
| Response Elements | 1 | 2009 | 17 | 0.080 |
Why?
|
| Transgenes | 1 | 2009 | 50 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 96 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 111 | 0.070 |
Why?
|
| Animals, Newborn | 2 | 2005 | 120 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 255 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2009 | 821 | 0.070 |
Why?
|
| Kidney | 1 | 2011 | 523 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2022 | 1844 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 475 | 0.060 |
Why?
|
| Quality of Life | 2 | 2022 | 962 | 0.060 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2005 | 10 | 0.060 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2005 | 7 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 52 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 91 | 0.060 |
Why?
|
| Gap Junctions | 1 | 2005 | 3 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2005 | 97 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2005 | 101 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 881 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 101 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1014 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2023 | 91 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2022 | 67 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 128 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2023 | 694 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 25 | 0.040 |
Why?
|
| United States | 2 | 2020 | 4118 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 109 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 191 | 0.040 |
Why?
|
| Pregnancy | 1 | 2023 | 981 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 181 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 240 | 0.040 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 8 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2019 | 45 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 56 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 99 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 877 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 76 | 0.040 |
Why?
|
| Heart Septum | 1 | 2018 | 4 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 66 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 93 | 0.040 |
Why?
|
| Triage | 1 | 2019 | 75 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 241 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 205 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2019 | 123 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2018 | 120 | 0.030 |
Why?
|
| Prognosis | 1 | 2022 | 1545 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 498 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 486 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 34 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 471 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 54 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 42 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 563 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 764 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 531 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 565 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2015 | 47 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 891 | 0.030 |
Why?
|
| Swine | 1 | 2015 | 216 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 2736 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 594 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2011 | 4 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 39 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4034 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 3642 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2011 | 72 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 124 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 164 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 309 | 0.020 |
Why?
|
| Shear Strength | 1 | 2009 | 10 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2009 | 43 | 0.020 |
Why?
|
| Hela Cells | 1 | 2009 | 80 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2009 | 80 | 0.020 |
Why?
|
| Cattle | 1 | 2009 | 108 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 134 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 209 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 197 | 0.020 |
Why?
|
| Connexin 43 | 1 | 2005 | 5 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 71 | 0.010 |
Why?
|
| Heart Conduction System | 1 | 2005 | 78 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 497 | 0.010 |
Why?
|